Incorporating COVID-19 into Acute Febrile Illness Surveillance Systems, Belize, Kenya, Ethiopia, Peru, and Liberia, 2020-2021
Existing acute febrile illness (AFI) surveillance systems can be leveraged to identify and characterize emerging pathogens, such as SARS-CoV-2, which causes COVID-19. The US Centers for Disease Control and Prevention collaborated with ministries of health and implementing partners in Belize, Ethiopia, Kenya, Liberia, and Peru to adapt AFI surveillance systems to generate COVID-19 response information. Staff at sentinel sites collected epidemiologic data from persons meeting AFI criteria and specimens for SARS-CoV-2 testing. A total of 5,501 patients with AFI were enrolled during March 2020-October 2021; >69% underwent SARS-CoV-2 testing. Percentage positivity for SARS-CoV-2 ranged from 4% (87/2,151, Kenya) to 19% (22/115, Ethiopia). We show SARS-CoV-2 testing was successfully integrated into AFI surveillance in 5 low- to middle-income countries to detect COVID-19 within AFI care-seeking populations. AFI surveillance systems can be used to build capacity to detect and respond to both emerging and endemic infectious disease threats.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 28(2022), 13 vom: 28. Dez., Seite S34-S41 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2022 Date Revised 19.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid2813.220898 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350146209 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350146209 | ||
| 003 | DE-627 | ||
| 005 | 20231226044322.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2813.220898 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350146209 | ||
| 035 | |a (NLM)36502419 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shih, David C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incorporating COVID-19 into Acute Febrile Illness Surveillance Systems, Belize, Kenya, Ethiopia, Peru, and Liberia, 2020-2021 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2022 | ||
| 500 | |a Date Revised 19.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Existing acute febrile illness (AFI) surveillance systems can be leveraged to identify and characterize emerging pathogens, such as SARS-CoV-2, which causes COVID-19. The US Centers for Disease Control and Prevention collaborated with ministries of health and implementing partners in Belize, Ethiopia, Kenya, Liberia, and Peru to adapt AFI surveillance systems to generate COVID-19 response information. Staff at sentinel sites collected epidemiologic data from persons meeting AFI criteria and specimens for SARS-CoV-2 testing. A total of 5,501 patients with AFI were enrolled during March 2020-October 2021; >69% underwent SARS-CoV-2 testing. Percentage positivity for SARS-CoV-2 ranged from 4% (87/2,151, Kenya) to 19% (22/115, Ethiopia). We show SARS-CoV-2 testing was successfully integrated into AFI surveillance in 5 low- to middle-income countries to detect COVID-19 within AFI care-seeking populations. AFI surveillance systems can be used to build capacity to detect and respond to both emerging and endemic infectious disease threats | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Belize | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Ethiopia | |
| 650 | 4 | |a Kenya | |
| 650 | 4 | |a Liberia | |
| 650 | 4 | |a Peru | |
| 650 | 4 | |a SARS | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a acute disease | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a fever | |
| 650 | 4 | |a global health | |
| 650 | 4 | |a incidence | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a sentinel surveillance | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a zoonoses | |
| 700 | 1 | |a Silver, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Henao, Olga L |e verfasserin |4 aut | |
| 700 | 1 | |a Alemu, Aynalem |e verfasserin |4 aut | |
| 700 | 1 | |a Audi, Allan |e verfasserin |4 aut | |
| 700 | 1 | |a Bigogo, Godfrey |e verfasserin |4 aut | |
| 700 | 1 | |a Colston, Josh M |e verfasserin |4 aut | |
| 700 | 1 | |a Edu-Quansah, Elijah P |e verfasserin |4 aut | |
| 700 | 1 | |a Erickson, Timothy A |e verfasserin |4 aut | |
| 700 | 1 | |a Gashu, Andargachew |e verfasserin |4 aut | |
| 700 | 1 | |a Gbelee, G Burgess |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Gunter, Sarah M |e verfasserin |4 aut | |
| 700 | 1 | |a Kosek, Margaret N |e verfasserin |4 aut | |
| 700 | 1 | |a Logan, Gorbee G |e verfasserin |4 aut | |
| 700 | 1 | |a Mackey, Joy M |e verfasserin |4 aut | |
| 700 | 1 | |a Maliga, Adrianna |e verfasserin |4 aut | |
| 700 | 1 | |a Manzanero, Russell |e verfasserin |4 aut | |
| 700 | 1 | |a Morazan, Gerhaldine |e verfasserin |4 aut | |
| 700 | 1 | |a Morey, Francis |e verfasserin |4 aut | |
| 700 | 1 | |a Munoz, Flor M |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Kristy O |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Thelma V |e verfasserin |4 aut | |
| 700 | 1 | |a Olortegui, Maribel Paredes |e verfasserin |4 aut | |
| 700 | 1 | |a Yori, Pablo Penataro |e verfasserin |4 aut | |
| 700 | 1 | |a Ronca, Shannon E |e verfasserin |4 aut | |
| 700 | 1 | |a Schiaffino, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Tayachew, Adamu |e verfasserin |4 aut | |
| 700 | 1 | |a Tedasse, Musse |e verfasserin |4 aut | |
| 700 | 1 | |a Wossen, Mesfin |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Denise R |e verfasserin |4 aut | |
| 700 | 1 | |a Angra, Pawan |e verfasserin |4 aut | |
| 700 | 1 | |a Balish, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Farron, Madeline |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Herman-Roloff, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Hicks, Victoria J |e verfasserin |4 aut | |
| 700 | 1 | |a Hunsperger, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Kazazian, Lilit |e verfasserin |4 aut | |
| 700 | 1 | |a Mikoleit, Matt |e verfasserin |4 aut | |
| 700 | 1 | |a Munyua, Peninah |e verfasserin |4 aut | |
| 700 | 1 | |a Munywoki, Patrick K |e verfasserin |4 aut | |
| 700 | 1 | |a Namwase, Angella Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Onyango, Clayton O |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Peruski, Leonard F |e verfasserin |4 aut | |
| 700 | 1 | |a Sugerman, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Gutierrez, Emily Zielinski |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Adam L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 28(2022), 13 vom: 28. Dez., Seite S34-S41 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:13 |g day:28 |g month:12 |g pages:S34-S41 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid2813.220898 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 13 |b 28 |c 12 |h S34-S41 | ||